Product Highlight - VPRIV

Active ingredient: Velaglucerase alfa

Indication: Long-term enzyme replacement therapy (ERT) in patients w/ type 1 Gaucher disease.

Dosage & Administration: Administer as a 60-min IV infusion. Recommended dose: 60 u/kg administered every other wk. Dose adjustments can be made on an individual basis based on achievement & maintenance of therapeutic goals. Clinical studies have evaluated doses ranging from 15-60 u/kg every other wk.